Copy Link Print Information

Lenzilumab

(Synonyms: KB 003)
2 Cited Publications
Revisión del cliente

Based on 2 publication(s) in Google Scholar

Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.64%
  • No. CAS: 1229575-09-0
  • Peso molecular:145.72 kDa
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Lenzilumab
  • Experimental Validation Results for Lenzilumab
  • Experimental Validation Results for Lenzilumab
  • Experimental Validation Results for Lenzilumab
  • Lenzilumab Chemical Structure
    Lenzilumab Chemical Structure
No. CAS: 1229575-09-0
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Lenzilumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Lenzilumab

More
Customer Validation & Images
Others
  • Others
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Loaded Lenzilumab on AHC2 biosensor, can bind GM-CSF Protein, Human (His, HY-P7016C) with an affinity constant of 5.364E-10 M as determined in BLI assay.

  • 1/16

    Lenzilumab(HY-P99207) neutralizes Recombinant Human GM-CSF (HY-P7016A) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.02545μg/mL in the presence of 0.5 ng/mL Recombinant Human GM-CSF.

  • 1/16

    Lenzilumab purchased from MedChemExpress. Usage Cited in: Arthritis Res Ther. 2025 Sep 26;27(1):180. [Abstract]

    Customer Validation
     Extracellular acidification rate (ECAR) measured by Seahorse assay in HMDMs exposed to RA serum with or without IL-1RN, infliximab, or lenzilumab (10 µg/mL).

  • Lenzilumab Chemical Structure
    1/16
  • Lenzilumab
  • Loaded Lenzilumab on AHC2 biosensor, can bind GM-CSF Protein, Human (His, HY-P7016C) with an affinity constant of 5.364E-10 M as determined in BLI assay.
  • Lenzilumab(HY-P99207) neutralizes Recombinant Human GM-CSF (HY-P7016A) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.02545μg/mL in the presence of 0.5 ng/mL Recombinant Human GM-CSF.